Huateng Pharma Develops Remdesivir & Favipiravir API & Intermediates For COVID-19 Research Purpose

CHANGSHA, China - April 23, 2020 - PRLog -- The 2019 novel coronavirus (COVID-19) has spread rapidly since its recent identification in patients with severe pneumonia in Wuhan, China. The pandemic has spread to over 150 countries and territories. Vaccines and treatment options for COVID-19 are currently being investigated around the world. There's some evidence that certain medications may have the potential to be effective with regard to preventing illness or treating the symptoms of COVID-19.

In this phase of growing threat, Huateng Pharma plays its parts by providing the necessary drug intermediates which might be used for the research purpose of coronavirus treatment. We are able to provide the production of potential COVID-19 drugs Remdesivir & Favipiravir API & Intermediates with capacities varying from gram to kilograms.

Remdesivir, also known as GS-5734, is a novel antiviral drug in the class of nucleotide analogs developed by Gilead Sciences. In February 2020 Remdesivir was being studied for experimental treatment of the emergent COVID-19 (novel coronavirus) disease.

CAS# 55094-52-5

CAS# 159326-68-8

CAS# 1191237-69-0

CAS# 1355357-49-1
Remdesivir N-4 intermediate

CAS# 1191237-80-5

Remdesivir N-2 intermediate

CAS# 946511-97-3
Remdesivir amino ester compound

CAS# 1355049-92-1
Remdesivir Chloro compound

CAS # 1191578-98-9
2-(3-((4-((Ethoxyimino)methyl)-5-(4-(trifluoromethoxy)phenyl)isoxazol-3-yl)methoxy)phenyl)acetic acid

CAS # 1809249-37-3
Remdesivir API

Favipiravir, also known as T-705 or Avigan, is an antiviral drug being developed by Toyama Chemical (Fujifilm group) of Japan with activity against many RNA viruses. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (novel coronavirus) disease.

CAS# 55321-99-8

CAS# 259793-88-9

CAS# 356783-16-9

CAS# 356783-28-3

CAS# 356783-31-8

CAS# 259793-96-9

About Us:
Hunan Huateng Pharmaceutical Co., Ltd. is a leading pharmaceutical company focusing on the creation of long-acting targeted new drugs. The company has extensive experience in the development of new antiviral drugs that can treat epidemic influenza, COVID19, H7N9, and H5N1 avian influenza, including Remdesivir, Favipiravir ,Oseltamivir, Baloxavir Marboxil, and others.

Sonia Lee
Source: » Follow
Posted By:*** Email Verified
Location:Changsha - Hunan - China
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Huateng Pharma News
Most Viewed
Daily News

Like PRLog?
Click to Share